Elutia receives FDA clearance for antibiotic-eluting bioenvelope EluPro for cardiac and neuromodulation devices

ELUTIA INC.

FDA cleared EluPro, first antibiotic-eluting bioenvelope, for pacemakers, defibrillators, neurostimulators, and neuromodulators.
Targets $600M US implantable electronic device protection market; no other biologic competitor currently.
Delivers rifampin and minocycline embedded in extracellular matrix to reduce infection, migration, and erosion complications.
Additional indications expand addressable market to neurostimulation/modulation, estimated at $8B worldwide.
Elutia plans national CIED launch in H2 2024; adjacent neuro markets prioritized for expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.